ArticleStem cells translational medicine2020
Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.
Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Translating potential into practice: the evolving landscape of neural stem cell therapeutics in clinical applications.Annals of medicine and surgery (2012) · 2026Review
- Ethical and Regulatory Considerations Related to Regenerative Medicine.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025Review
- Development of Stem Cell Data Systems and Associated Data Standards for Cell Therapy.Advances in experimental medicine and biology · 2025Review
- Review
- Attitudes Towards Standardization of Mesenchymal Stromal Cells-A Qualitative Exploration of Expert Views.Stem cells translational medicine · 2023Article
- Review
- How to establish infrastructures to achieve more efficient regenerative medicine?Cell and tissue banking · 2023Review
- Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology.NAM perspectives · 2023Review
- Stem Cell Therapy: From Idea to Clinical Practice.International journal of molecular sciences · 2022Review
- An urgent need for standardization of stem cells and stem cell-derived products toward clinical applications.Stem cells translational medicine · 2021Article
- Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.Stem cell reports · 2021Review
- Emerging workforce readiness in regenerative healthcare.Regenerative medicine · 2021Article
- Regenerative medicine clinical readiness.Regenerative medicine · 2021Review
- Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward.Frontiers in bioengineering and biotechnology · 2021Article
- Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.Stem cells translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven "stem cell" interventions. At this juncture, it is vital to be supporting the continued development of promising regenerative medicine products while protecting patients from the risks posed by unproven interventions. Various stakeholders, including governments, patient groups, medical societies, and the media, are committed to this outcome. In this perspective, we draw on our experience gained from partnerships in developing regenerative medicine products to identify technical, organizational, and ethical benchmarks for the responsible delivery of regenerative medicine treatments. These benchmarks may serve as the basis for policy interventions intended to drive the responsible delivery of stem cell and regenerative medicine products. Our particular focus is on a California-based policy, but the suggested benchmarks are broadly applicable to national and international jurisdictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.